Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke increased and prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.
Clinuvel Pharmaceuticals Dividend Announcement
• Clinuvel Pharmaceuticals announced a annually dividend of $0.03 per ordinary share which will be made payable on 2024-09-30. Ex dividend date: 2024-09-09
• Clinuvel Pharmaceuticals annual dividend for 2024 was $0.03
• Clinuvel Pharmaceuticals annual dividend for 2023 was $0.03
• Clinuvel Pharmaceuticals's trailing twelve-month (TTM) dividend yield is 0.38%
• Clinuvel Pharmaceuticals's payout ratio for the trailing twelve months (TTM) is 6.93%
• Clinuvel Pharmaceuticals's dividend growth over the last five years (2018-2023) was 17.98% year
Clinuvel Pharmaceuticals Dividend History
Ex-Div date | Dividend amount | Dividend type | Pay date |
---|---|---|---|
2024-09-09 | $0.03 | annually | 2024-09-30 |
2023-09-07 | $0.03 | annually | 2023-10-02 |
2022-09-09 | $0.03 | annually | 2022-10-03 |
2021-09-03 | $0.02 | annually | 2021-09-27 |
2020-09-04 | $0.02 | annually | 2020-09-28 |
2019-09-06 | $0.02 | annually | 2019-09-30 |
2018-09-20 | $0.01 | annually | 2018-10-18 |
Clinuvel Pharmaceuticals Dividend per year
Clinuvel Pharmaceuticals Dividend growth
Clinuvel Pharmaceuticals Dividend Yield
Clinuvel Pharmaceuticals current trailing twelve-month (TTM) dividend yield is 0.38%. Interested in purchasing Clinuvel Pharmaceuticals stock? Use our calculator to estimate your expected dividend yield:
Clinuvel Pharmaceuticals Financial Ratios
Clinuvel Pharmaceuticals Dividend FAQ
Other factors to consider when evaluating Clinuvel Pharmaceuticals as a dividend stock include its dividend yield, dividend growth, payout ratio, and the sustainability of its dividend payments given its earnings and cash flow. These factors can provide insight into the company's ability to maintain or increase its dividend in the future.
Place an order: Use the brokerage's trading platform to place an order to buy Clinuvel Pharmaceuticals stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.
1. Determination of Dividend: Clinuvel Pharmaceuticals's board of directors reviews the company's financial performance, cash flow, future investment needs, and other relevant factors to determine the amount and timing of dividend payments.
2. Dividend Declaration: Once the board approves a dividend, Clinuvel Pharmaceuticals publicly announces the dividend amount, currency, and the ex-dividend date. The ex-dividend date is the date on or after which the buyer of the stock will not be eligible to receive the upcoming dividend payment.
3. Record Date: The record date is the date on which the company checks its records to identify shareholders who are eligible to receive the dividend. Only shareholders on record as of this date will receive the dividend.
4. Payment Date: On the designated payment date, Clinuvel Pharmaceuticals distributes the dividend to eligible shareholders. The dividend is usually paid in the form of cash directly into the shareholder's brokerage account or through other designated payment methods.
5. Tax Implications: Dividends received from Clinuvel Pharmaceuticals are generally taxable as income. Shareholders may need to report dividend income on their tax returns and pay applicable taxes according to their jurisdiction's tax regulations.
1. Record Date: Clinuvel Pharmaceuticals sets a record date, which is the date on which the company checks its records to determine the eligible shareholders. Only those who are shareholders on record as of this date will receive the dividend.
2. Payment Date: On the designated payment date, Clinuvel Pharmaceuticals distributes the dividend to eligible shareholders. The payment is usually made electronically, directly into the shareholder's brokerage account or bank account.
3. Currency: Clinuvel Pharmaceuticals declares the currency in which the dividend will be paid. Depending on the shareholder's location and the currency election made by the shareholder, the dividend will be converted to the appropriate currency during the payment process.
To assess the safety of Clinuvel Pharmaceuticals's dividend, it is crucial to analyze the company's financial health, debt levels, cash flow generation, and ability to sustain dividend payments over the long term. Additionally, monitoring the company's future earnings, cash flow projections, and management's commitment to dividend policies can provide valuable insights.
It is recommended to review Clinuvel Pharmaceuticals's financial reports, official announcements, and consult with financial advisors or experts who have access to the most current and comprehensive information about the company's financial situation.